Brittany Cote

Articles

Expert Highlights Advantage of Triplet Therapies in Relapsed/Refractory Myeloma

February 28th 2020

Andrew Yee, MD, reflects on recent clinical trials in multiple myeloma that focused on novel multidrug regimens.

FDA Takes Action on Safety Measures With Laparoscopic Power Morcellators for Gynecologic Surgery

February 28th 2020

In an effort to make the use of laparoscopic power morcellators a safer and more effective choice in gynecologic surgeries, the FDA has released a statement that it will be putting a handful of strategies and recommendations in place.

Gemtuzumab Ozogamicin Misses Early EFS Endpoint, as Phase III Study Continues in NPM1+ AML

February 26th 2020

Gemtuzumab ozogamicin in combination with intensive induction therapy was associated with a higher early death rate compared with induction therapy alone in patients with NPM1-mutated acute myeloid leukemia.

Neoadjuvant and Adjuvant ADT With Dose-Escalated PRT Show Similar Outcomes in Prostate Cancer

February 26th 2020

Neoadjuvant and concurrent androgen-deprivation therapy (ADT) with dose-escalated prostate radiotherapy (PRT) and concurrent and adjuvant ADT plus dose-escalated PRT were found to have no statistically significant differences in biochemical relapse-free survival in patients with localized prostate cancer, according to results of a phase III trial.

CAR-T Leads Advances Across Lymphomas, But Further Research Needed

February 25th 2020

Dimitrios Tzachanis, MD, PhD, discusses updates and remaining questions with CAR T-cell therapy.

Osimertinib Shows Efficacy in CNS and Leptomeningeal Mets in EGFR+ NSCLC

February 21st 2020

Osimertinib, at 160 mg daily, demonstrated efficacy in the central nervous system and a manageable safety profile in patients with EGFR-mutant advanced non–small cell lung cancer who have leptomeningeal metastases.

Precision Medicine Approaches Evolving With CDK4/6, PI3K Inhibitors in HR+ Breast Cancer

February 21st 2020

Sara Tolaney, MD, MPH, reflects on the encouraging findings observed with CDK4/6 inhibitors in combination with endocrine therapy in the treatment of patients with hormone receptor-positive, HER2-negative breast cancer.

Immunotherapy Advances to Frontline in NSCLC, But More Work Remains

February 20th 2020

Ronald Natale, MD, expands on the recent developments with immunotherapy in advanced non–small cell lung cancer.

Molecular Testing Essential in NSCLC Management

February 19th 2020

Jean Lopategui, MD, reflects on the use of molecular testing for patients with non–small cell lung cancer.

Adjuvant Ipilimumab Improves OS in High-Risk Melanoma

February 18th 2020

Adjuvant treatment with ipilimumab, when given at a 3-mg/kg dose, was found to improve overall survival compared with high-dose interferon alfa in patients with high-risk melanoma.

Genetic Testing, PARP Inhibitors Lead to Transformed Pancreatic Cancer Paradigm

February 15th 2020

Eileen O’Reilly, MD, reflects on the treatment advances that are expanding the pancreatic cancer paradigm.

Expert Highlights Latest Developments in Early and Locally Advanced Pancreatic Cancer

February 14th 2020

Diane Simeone, MD, discusses recent data on neoadjuvant and adjuvant therapy for patients with locally advanced or resectable pancreatic cancer, and questions surrounding germline testing for earlier identification of this disease.

Value-Based Care With Two-Sided Risk a Preference in Upcoming Oncology Care Model

February 13th 2020

Oncology practices that are participating in the Centers for Medicare & Medicaid Innovation’s Oncology Care Model are willing to take on two-sided risk with value-based care and shift from a fee-for-service approach.

CD19-Directed CAR-NK Cell Therapy Elicits Responses in Non-Hodgkin Lymphoma and CLL

February 13th 2020

Treatment with a CD19-targeted CAR-natural killer–cell therapy led to a 73% objective response rate, including 7 complete responses, in patients with relapsed/refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia.

NEJM Data Show Volume CT Screening Lowers Mortality in High-Risk Lung Cancer

February 12th 2020

Patients with high-risk lung cancer who underwent volume CT screening had a significantly lower lung cancer mortality compared with those who were not screened.

CTC Detection Linked to Relapse in Stage III Melanoma

February 12th 2020

The presence of circulating tumor cell was found to be independently associated with relapse in patients with stage III melanoma, suggesting that CTC assessment may be useful in identify patients who are at risk for relapse and could benefit from adjuvant therapy.

Pathological Fractures Linked to Inferior OS in Adults With Osteosarcoma

February 12th 2020

Pathological fractures in adult patients with high-grade osteosarcoma of the extremities potentially correlates with inferior overall survival.

Schwartzberg Sheds Light on Rise of Biosimilars in Oncology

February 6th 2020

Lee Schwartzberg, MD, FACP, advocates for the increased use of biosimilars in oncology and discusses the benefits of these agents for patients and providers.

Research Efforts Continue With Radiation Therapy in Breast Cancer

February 6th 2020

Eileen Connolly, MD, PhD, reflects on novel radiation techniques, as well as ongoing research and challenges with radiation therapy in breast cancer.

Expert Outlines Next Steps for Liquid Biopsies in Oncology

February 4th 2020

Benjamin P. Levy, MD, discusses the next steps with liquid biopsies in non–small cell lung cancer and its broader use in oncology.